{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T23:47:30Z","timestamp":1776296850098,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ygyno.2017.04.006","type":"journal-article","created":{"date-parts":[[2017,4,18]],"date-time":"2017-04-18T00:45:28Z","timestamp":1492476328000},"page":"34-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women"],"prefix":"10.1016","volume":"146","author":[{"given":"William D.","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart R.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola A.","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"6667","key":"10.1016\/j.ygyno.2017.04.006_bb0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.298.6667.147","article-title":"Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study","volume":"298","author":"Persson","year":"1989","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.006_bb0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ygyno.2005.06.029","article-title":"Endometrial cancer in young, normal-weight women","volume":"99","author":"Schmeler","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.04.006_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","article-title":"Understanding obesity and endometrial cancer risk: opportunities for prevention","volume":"205","author":"Schmandt","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ygyno.2017.04.006_bb0025","first-page":"1531","article-title":"Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review","volume":"11","author":"Kaaks","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"3","key":"10.1016\/j.ygyno.2017.04.006_bb0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1634\/theoncologist.2013-0445","article-title":"Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer","volume":"20","author":"Park","year":"2015","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.006_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2012.01.003","article-title":"Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review","volume":"125","author":"Gunderson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.04.006_bb0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","article-title":"Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)","volume":"49","author":"Park","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cct.2014.06.014","article-title":"Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device +\/\u2212 metformin +\/\u2212 weight loss in endometrial cancer (feMME) trial","volume":"39","author":"Hawkes","year":"2014","journal-title":"Contemp. Clin. Trials"},{"issue":"10","key":"10.1016\/j.ygyno.2017.04.006_bb0050","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/1933719114522517","article-title":"Complex atypical hyperplasia of the endometrium: differences in outcome following conservative management of pre- and postmenopausal women","volume":"21","author":"Brownfoot","year":"2014","journal-title":"Reprod Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejogrb.2011.06.025","article-title":"Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia","volume":"159","author":"Haoula","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2017.04.006_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2014.02.020","article-title":"Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin","author":"Simpson","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.04.006_bb0065","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mob.2002.122130","article-title":"Intrauterine progesterone treatment of early endometrial cancer","volume":"186","author":"Montz","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.04.006_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/PGP.0000000000000177","article-title":"Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"33","author":"Zaino","year":"2014","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.04.006_bb0075","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1097\/AOG.0b013e31828d6186","article-title":"Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma","volume":"121","author":"Hubbs","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.006_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1096-9896(199610)180:2<223::AID-PATH635>3.0.CO;2-H","article-title":"Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody","volume":"180","author":"Huang","year":"1996","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.006_bb0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2005.10.030","article-title":"Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia","volume":"101","author":"Vereide","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2017.04.006_bb0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/OGX.0b013e31822f8f66","article-title":"Fertility-sparing management of endometrial adenocarcinoma","volume":"66","author":"Dorais","year":"2011","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.ygyno.2017.04.006_bb0095","first-page":"1","article-title":"Safety and comfort of long-term continuous combined transdermal estrogen and intrauterine levonorgestrel administration for postmenopausal hormone substitution - a review","author":"Wildemeersch","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ygyno.2017.04.006_bb0100","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen","volume":"12","author":"Dominick","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ygyno.2017.04.006_bb0105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/09513590.2012.730579","article-title":"Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women","volume":"29","author":"Morelli","year":"2013","journal-title":"Gynecol. Endocrinol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.04.006_bb0110","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/humrep\/det320","article-title":"LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study","volume":"28","author":"Gallos","year":"2013","journal-title":"Hum. Reprod."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2003.10.021","article-title":"Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma","volume":"92","author":"Dahmoun","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2017.04.006_bb0120","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/AOG.0b013e31821188ad","article-title":"Continuation and satisfaction of reversible contraception","volume":"117","author":"Peipert","year":"2011","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.04.006_bb0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730776X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730776X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T06:42:49Z","timestamp":1575614569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730776X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S009082581730776X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}